鲁抗医药2025年半年度业绩说明会问答实录

Core Viewpoint - The company held a successful half-year performance briefing on September 19, 2025, with full interaction with investors, addressing various inquiries regarding stock issuance, project updates, and financial performance [1][2]. Group 1: Stock Issuance and Financial Performance - The company has submitted a registration application to the China Securities Regulatory Commission for a stock issuance to specific investors, following the Shanghai Stock Exchange's review [1][2]. - The pricing for the stock issuance will be no less than 80% of the average trading price over the 20 trading days prior to the pricing date [1][2]. - The company reported a significant profit decline in the first half of 2025, primarily due to non-recurring gains from asset disposals in the previous year, which amounted to 156 million [2][3]. Group 2: Project Updates - The trans-aconitic acid green bio-manufacturing project commenced production on May 29, 2025, marking a significant step towards industrialization [1]. - The company has over 60 biological pesticide products in production and sales, with three innovative biological pesticides currently under registration [1][2]. - The trans-aconitic acid pesticide formulation is in the testing phase, with plans to submit registration materials in the first quarter of 2026 [1][2]. Group 3: R&D and Product Development - The company has three I-class innovative drugs in clinical trials: TRN-157 for chronic obstructive pulmonary disease in Phase II, CIGB-814 for rheumatoid arthritis in Phase I, and CMS-203, a PDE5 inhibitor for male erectile dysfunction in Phase II [2][3]. - The company is focusing on enhancing operational efficiency and profitability to improve its investment value amidst a competitive pharmaceutical market [2][3].